Cargando…

Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report

While checkpoint inhibitor therapy has revolutionized the treatment landscape of some solid tumors, it has shown limited efficacy in metastatic castration-resistant prostate cancers (mCRPC). A small (~3–5%) but clinically distinct subset of mCRPC tumors have a DNA mismatch repair deficiency (dMMR) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reed-Perino, Darien E, Lai, Michael, Yu, Evan Y, Schweizer, Michael T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230978/ https://www.ncbi.nlm.nih.gov/pubmed/37220954 http://dx.doi.org/10.1136/jitc-2023-006794

Ejemplares similares

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

(177)Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
por: Sanli, Yasemin, et al.
Publicado: (2021)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

Single-dose (177)Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial
por: Aggarwal, Rahul, et al.
Publicado: (2023)

Clinical Characterization of Mismatch Repair Gene-Deficient Metastatic Castration-Resistant Prostate Cancer
por: Ye, Senlin, et al.
Publicado: (2020)

PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?
por: Giraudet, Anne-Laure, et al.
Publicado: (2021)

Association Between Survival and Metastatic Site in Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab
por: Saberzadeh-Ardestani, Bahar, et al.
Publicado: (2023)

Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
por: Han, Harry J., et al.
Publicado: (2020)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
por: Gaudreault, Mathieu, et al.
Publicado: (2023)

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer
por: Drake, Charles G., et al.
Publicado: (2021)

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies
por: Graham, Laura S., et al.
Publicado: (2020)

Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
por: Fujiwara, Motohiro, et al.
Publicado: (2020)

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Juzeniene, Asta, et al.
Publicado: (2021)

VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021)

Determinants of outcome following PSMA-based radioligand therapy and mechanisms of resistance in patients with metastatic castration-resistant prostate cancer
por: Kostos, Louise, et al.
Publicado: (2023)

PSMA-PET Detection of Unusual Metastases in Castrate-Sensitive Prostate Carcinoma
por: Harris, Nathanial, et al.
Publicado: (2023)

Title unknown, CERN-ALEPH-2000-081
por: CERN. Geneva. ALEPH
Publicado: (2000)

Anticancer activity of the iron facilitator LS081
por: Li, Zhen, et al.
Publicado: (2011)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

(213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
por: Sathekge, Mike, et al.
Publicado: (2017)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer
por: Carlson, Alexander S., et al.
Publicado: (2020)

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
por: Kageyama, Takumi, et al.
Publicado: (2022)

Response assessment using (68)Ga-PSMA ligand PET in patients undergoing (177)Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
por: Grubmüller, Bernhard, et al.
Publicado: (2018)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

(177)Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis
por: Sadaghiani, Mohammad S., et al.
Publicado: (2022)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
por: Nghiem, Belinda, et al.
Publicado: (2016)

Neurotoxicity of Synthetic Cannabinoids JWH-081 and JWH-210
por: Cha, Hye Jin, et al.
Publicado: (2015)

Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
por: Groener, Daniel, et al.
Publicado: (2021)

(177)Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art
por: AlSadi, Rahaf, et al.
Publicado: (2022)

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)
por: Emmett, Louise, et al.
Publicado: (2023)

Predictive and prognostic potential of pretreatment (68)Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
por: Assadi, Majid, et al.
Publicado: (2022)

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2022)

Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma
por: Damato, Bertil E., et al.
Publicado: (2019)

Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
por: Yadav, Madhav Prasad, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_et9hmfbc3rug7d8fi8q4f58aq6